scholarly journals Long noncoding RNA MALAT-1 is a novel inflammatory regulator in human systemic lupus erythematosus

Oncotarget ◽  
2017 ◽  
Vol 8 (44) ◽  
pp. 77400-77406 ◽  
Author(s):  
Huaxia Yang ◽  
Naixin Liang ◽  
Min Wang ◽  
Yunyun Fei ◽  
Jian Sun ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Human Systemic Lupus Erythematosus ◽  
Systemic Lupus

Organized Intraglomerular Deposits in NZB Mouse Disease

1971 ◽  
Vol 29 ◽  
pp. 544-545
Author(s):  
Francis R. Comerford ◽  
Alan S. Cohen
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antinuclear Antibodies ◽  
Human Systemic Lupus Erythematosus ◽  
Systemic Lupus ◽  
Glomerular Lesion ◽  
Ultrastructural Studies ◽  
Dense Deposits ◽  
Experimental Nephritis ◽  
Glomerular Lesions

Mice of the inbred NZB strain develop a spontaneous disease characterized by autoimmune hemolytic anemia, positive lupus erythematosus cell tests and antinuclear antibodies and nephritis. This disease is analogous to human systemic lupus erythematosus. In ultrastructural studies of the glomerular lesion in NZB mice, intraglomerular dense deposits in mesangial, subepithelial and subendothelial locations were described. In common with the findings in many examples of human and experimental nephritis, including many cases of human lupus nephritis, these deposits were amorphous or slightly granular in appearance with no definable substructure.We have recently observed structured deposits in the glomeruli of NZB mice. They were uncommon and were found in older animals with severe glomerular lesions by morphologic criteria. They were seen most commonly as extracellular elements in subendothelial and mesangial regions. The deposits ranged up to 3 microns in greatest dimension and were often adjacent to deposits of lipid-like round particles of 30 to 250 millimicrons in diameter and with amorphous dense deposits.

scholarly journals FAS mRNA editing in human systemic lupus erythematosus

2011 ◽  
Vol 32 (11) ◽  
pp. 1268-1277 ◽  
Author(s):  
Jianming Wu ◽  
Fenglong Xie ◽  
Kun Qian ◽  
Andrew W. Gibson ◽  
Jeffrey C. Edberg ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Human Systemic Lupus Erythematosus ◽  
Mrna Editing ◽  
Systemic Lupus ◽  
Fas Mrna

scholarly journals Confirmation of genetic linkage between human systemic lupus erythematosus and chromosome 1q41

1999 ◽  
Vol 42 (9) ◽  
pp. 1902-1907 ◽  
Author(s):  
Kathy L. Moser ◽  
Courtney Gray-McGuire ◽  
Jennifer Kelly ◽  
Neeraj Asundi ◽  
Hua Yu ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Genetic Linkage ◽  
Human Systemic Lupus Erythematosus ◽  
Systemic Lupus ◽  
Chromosome 1Q41

Analysis of molecular heterogeneity of prolactin in human systemic lupus erythematosus

Lupus ◽  
2004 ◽  
Vol 13 (8) ◽  
pp. 575-583 ◽  
Author(s):  
M García ◽  
M E Colombani-Vidal ◽  
C C Zylbersztein ◽  
A Testi ◽  
J Marcos ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Molecular Heterogeneity ◽  
Human Systemic Lupus Erythematosus ◽  
Systemic Lupus

scholarly journals Development and Validation of a MicroRNA Panel to Differentiate Between Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus and Controls

2019 ◽  
Vol 47 (2) ◽  
pp. 188-196 ◽  
Author(s):  
Michelle J. Ormseth ◽  
Joseph F. Solus ◽  
Quanhu Sheng ◽  
Fei Ye ◽  
Qiong Wu ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Noncoding Rna ◽  
Characteristic Curve ◽  
Systemic Lupus ◽  
Control Subjects ◽  
Development And Validation ◽  
And Control ◽  
Bioinformatic Approach

Objective.MicroRNA (miRNA) are short noncoding RNA that regulate genes and are both biomarkers and mediators of disease. We used small RNA (sRNA) sequencing and machine learning methodology to develop an miRNA panel to reliably differentiate between rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and control subjects.Methods.Plasma samples from 167 RA and 91 control subjects who frequency-matched for age, race, and sex were used for sRNA sequencing. TIGER was used to analyze miRNA. DESeq2 and random forest analyses were used to identify a prioritized list of miRNA differentially expressed in patients with RA. Prioritized miRNA were validated by quantitative PCR, and lasso and logistic regression were used to select the final panel of 6 miRNA that best differentiated RA from controls. The panel was validated in a separate cohort of 12 SLE, 32 RA, and 32 control subjects. Panel efficacy was assessed by area under the receiver operative characteristic curve (AUC) analyses.Results.The final panel included miR-22-3p, miR-24-3p, miR-96-5p, miR-134-5p, miR-140-3p, and miR-627-5p. The panel differentiated RA from control subjects in discovery (AUC = 0.81) and validation cohorts (AUC = 0.71), seronegative RA (AUC = 0.84), RA remission (AUC = 0.85), and patients with SLE (AUC = 0.80) versus controls. Pathway analysis showed upstream regulators and targets of panel miRNA are associated with pathways implicated in RA pathogenesis.Conclusion.An miRNA panel identified by a bioinformatic approach differentiated between RA or SLE patients and control subjects. The panel may represent an autoimmunity signature, perhaps related to inflammatory arthritis, which is not dependent on active disease or seropositivity.

Sign in / Sign up

Export Citation Format

Share Document